Remedee Labs, a French start-up that specializes in non-pharmaceutical chronic pain management and just announced the positive results of its clinical study on osteoarthritis is strengthening its Board of Directors and its Advisory Board with the addition of two experienced healthcare executives: Florence DUPRÉ and JULIE FOSTER.
Florence DUPRÉ joins the Board of Directors
As a healthcare executive with over 28 years of experience in the field, Florence has contributed to numerous product launches for international pharmaceutical companies. After graduating from ESSEC and École Normale Supérieure ULM, Florence plunged into entrepreneurship, founding the French subsidiaries of BioAlliance Pharma (now Onxeo) and Vifor Pharma. She then joined AbbVie, where she had international responsibility for sales and transformation. Florence then became the President of the French subsidiary of Medtronic, the global healthcare technology leader. Florence has also served as a member of the Board of Directors and the Executive Board of the French National Association for Medical Technology and Industries (SNITEM) and the Management Board of the Rennes University Foundation.
“I am deeply honored to join the Board of Directors of Remedee Labs, which offers a unique solution to relieve chronic pain and support patients through their healthcare journey. I am excited to contribute my support and expertise to the team,” says Florence DUPRÉ.
Julie FOSTER joins the Advisory Board
Julie FOSTER is currently the Chief Operating Officer at Cerebral Therapeutics, a U.S. based clinical stage biopharmaceutical company dedicated to developing innovative and de-risked therapies for refractory neurological diseases. She previously spent over 34 years in a range of global executive roles at Medtronic, the medical technology leader worldwide, including as Vice President of Customer Experience at the Diabetes division, Vice President of the Cardiac and Vascular businesses in EMEA, and General Manager of Pain Therapies, where the activities she headed included neuromodulation.
Julie brings international experience and a strategic vision of healthcare, particularly pain care, to Remedee Labs. She will advise Remedee Labs on its development and growth, particularly in the US, where it earned FDA “breakthrough device” designation for its fibromyalgia management solution.
“I am looking forward to join the Advisory Board of Remedee Labs, a company that takes an innovative and comprehensive approach to chronic pain management. I believe that this solution has the potential to change millions of lives and I am thrilled to be able to contribute to its success,” says Julie FOSTER.
